A double-blind, randomized controlled trial of clobetasol versus pimecrolimus in patients with vulvar lichen sclerosus

Journal of the American Academy of Dermatology

Volumn 64, Issue 6, 2011, Pages

  Goldstein, Andrew T ^a   Creasey, Alia ^b   Pfau, Richard ^c   Phillips, Daniel ^d   Burrows, Lara J ^e  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c Anne Arundel County   (United States)

^d UNIVERSITY OF MARYLAND   (United States)

^e SUMMA HEALTH SYSTEM   (United States)

Author keywords

calcineurin inhibitor; corticosteroid; lichen sclerosus; pimecrolimus; vulva

Indexed keywords

CLOBETASOL; PIMECROLIMUS;

ABSENCE OF SIDE EFFECTS; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HERPES SIMPLEX; HUMAN; HUMAN TISSUE; INVESTIGATOR GLOBAL ASSESSMENT; LICHEN SCLEROSUS ET ATROPHICUS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SKIN BIOPSY; SKIN BURNING SENSATION; SKIN INFLAMMATION; SKIN PAIN; VAGINA PAIN; VAGINAL BURNING SENSATION; VISUAL ANALOG SCALE; VULVA;

ANTI-INFLAMMATORY AGENTS; CLOBETASOL; DOUBLE-BLIND METHOD; FEMALE; GLUCOCORTICOIDS; HUMANS; PAIN MEASUREMENT; TACROLIMUS; TREATMENT OUTCOME; VULVAR LICHEN SCLEROSUS;

EID: 79956160341     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2010.06.011     Document Type: Article

References (14)

1. Goldstein AT, Marinoff SC, Christopher K, Srodon M. Prevalence of vulvar lichen sclerosus in a general gynecology practice. J Reprod Med 2005;50:477-80. (Pubitemid 41022264)
2. Wallace HJ. Lichen sclerosus et atrophicus. Trans St Johns Hosp Dermatol Soc 1971;57:9-30.
3. Burrows LJ, Shaw HA, Goldstein AT. The vulvar dermatoses. J Sex Med 2008;5:276-83. (Pubitemid 351167737)
4. Neill SM, Tatnall FM, Cox NH. Guidelines for the management of lichen sclerosus. Br J Dermatol 2002;147:640-9. (Pubitemid 35286146)
5. Jensen JM, Pfeiffer S, Witt M, Bräutigam M, Neumann C, Weichenthal M, et al. Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. J Allergy Clin Immunol 2009;123:1124-33.
6. Queille-Roussel C, Paul C, Duteil L, Lefebvre MC, Rapatz G, Zagula M, Ortonne JP. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 2001;144:507-13. (Pubitemid 32232004)
7. Bornstein J, Heifetz S, Kellner Y, Stolar Z, Abramovici H. Clobetasol dipropionate 0.05% versus testosterone propionate 2% topical application for severe vulvar lichen sclerosus. Am J Obstet Gynecol 1998;178:80-4. (Pubitemid 28302799)
8. Sideri M, Origoni M, Spinaci L, Ferrari A. Topical testosterone in the treatment of vulvar lichen sclerosus. Int J Gynaecol Obstet 1994;46:53-6. (Pubitemid 24232071)
9. Goldstein AT, Marinoff SC, Christopher K. Pimecrolimus for the treatment of vulvar lichen sclerosus in a premenarchal girl. J Pediatr Adolesc Gynecol 2004;17:35-7. (Pubitemid 38315012)
10. Boms S, Gambichler T, Freitag M, Altmeyer P, Kreuter A. Pimecrolimus 1% cream for anogenital lichen sclerosus in childhood. BMC Dermatol 2004;4:14.
11. Goldstein AT, Marinoff SC, Christopher K. Pimecrolimus for the treatment of vulvar lichen sclerosus: a report of 4 cases. J Reprod Med 2004;49:778-80. (Pubitemid 39431172)
12. Nissi R, Eriksen H, Risteli J, Niemimaa M. Pimecrolimus cream 1% in the treatment of lichen sclerosus. Gynecol Obstet Invest 2007;63:151-4. (Pubitemid 46514803)
13. Oskay T, Sezer HK, Genc C, Kutluay L. Pimecrolimus 1% cream in the treatment of vulvar lichen sclerosus in postmenopausal women. Int J Dermatol 2007;46:527-32. (Pubitemid 46711440)
14. Kauppila S, Kotila V, Knuuti E, Vare PO, Vittaniemi P, Nissi R. The effect of topical pimecrolimus on inflammatory infiltrate in vulvar lichen sclerosus. Am J Obstet Gynecol 2010;202:181.e1-4.